The label for metformin hydrochloride received a significant update on 2025-04-23, with the addition of a boxed warning concerning the risk of lactic acidosis. This revision by the FDA highlights that postmarketing cases of metformin-associated lactic acidosis have been linked to severe outcomes, including death.
What this means
The new boxed warning on the metformin hydrochloride label, effective 2025-04-23, provides critical information for clinicians regarding the serious risk of lactic acidosis. The warning explicitly states that postmarketing cases of metformin-associated lactic acidosis have led to severe adverse events such as death, hypothermia, hypotension, and resistant bradyarrhythmias. A key aspect emphasized is that the onset of metformin-associated lactic acidosis is often subtle, which can complicate timely diagnosis and intervention. This update serves as a vital reminder for healthcare professionals to maintain a high index of suspicion for lactic acidosis in patients receiving metformin hydrochloride, especially those with predisposing risk factors. Awareness of these specific symptoms and the subtle nature of onset is crucial for mitigating the potentially fatal consequences of this adverse reaction.
Source
The information regarding this label revision was obtained from the FDA. The update to the metformin hydrochloride label, effective 2025-04-23, is documented on the DailyMed website, hosted by nlm.nih.gov.